Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment-Reference-Cited by-同舟云学术

Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment

Published:2016-05-29 Issue:3 Volume:82 Page:696-705
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Zhao Baiteng¹,Chen Robert²,O'Connor Owen A.³,Gopal Ajay K.⁴,Ramchandren Radhakrishnan⁵,Goy Andre⁶,Matous Jeffrey V.⁷,Fasanmade Adedigbo A.⁸,Manley Thomas J.¹,Han Tae H.⁹

Affiliation:

1. Seattle Genetics, Inc. Bothell WA

2. City of Hope Medical Center Duarte CA

3. Center for Lymphoid MalignanciesColumbia University Medical Center New York NY

4. University of Washington Seattle WA

5. Karmanos Cancer Institute Detroit MI

6. John Theurer Cancer Center at Hackensack University Medical Center Hackensack NJ

7. Colorado Blood Cancer Institute Denver CO

8. Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceuticals Limited Cambridge MA

9. Stemcentrx, Inc. South San Francisco CA USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.12988

Reference21 articles.

1. cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

2. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

3. Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

4. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

5. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody drug conjugates: Design implications for clinicians;Journal of Oncology Pharmacy Practice;2024-04-23

2. Development of a generalized pharmacokinetic model to characterize clinical pharmacokinetics of monomethyl auristatin E‐based antibody–drug conjugates;British Journal of Clinical Pharmacology;2024-04-02

3. Extravasation of brentuximab vedotin, an antibody-drug conjugate, in a patient with anaplastic large cell lymphoma;European Journal of Hospital Pharmacy;2024-03-06

4. Anticorps monoclonaux conjugués et bispécifiques en cancérologie – compte rendu de la Journée de Saint Louis 2022;Bulletin du Cancer;2023-12

5. A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study;Blood Research;2023-11-30